Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [3H]-SR 121463

被引:19
|
作者
Serradeil-Le Gal, C
Raufaste, D
Double-Cazanave, E
Guillon, G
Garcia, C
Pascal, M
Maffrand, JP
机构
[1] Sanofi Synthelabo Rech, Exploratory Res Dept, F-31036 Toulouse, France
[2] CCIPE, INSERM, U469, Montpellier, France
关键词
kidney; antidiuretic hormone; arginine vasopressin; homeostasis; water regulation; ligand;
D O I
10.1046/j.1523-1755.2000.00322.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. [H-3]-SR 121463 is the first radiolabeled selective nonpeptide vasopressin V-2 receptor antagonist ligand that has been reported to date. In the present work, we studied the binding properties of [H-3]-SR 121463 for renal V-2 receptors from animal and human origins. Methods. Binding studies were performed with [H-3]-SR 121463 in Chinese hamster ovary (CHO) cells transfected with the human V-2 receptor and in various kidney preparations expressing the native V-2 receptors (rat, rabbit, dog, pig, monkey, and human). Autoradiographies were performed in rat and human kidney sections. Results. [H-3]-SR 121463 binding to CHO cells stably transfected with the cloned human renal V-2 receptor was specific, highly stable, time dependent, saturable, and reversible. A single population of high-affinity binding sites was identified (K-d = 0.94 +/- 0.34 nmol/L, B-max = 9876 +/- 317 fmol/mg protein). Of note, [H-3]-SR 121463 revealed a higher number (about 40%) of V-3 sites than [H-3]-AVP in the same preparation. Displacement of [H-3]-SR 121463 binding by reference peptide and nonpeptide vasopressin/oxytocin compounds exhibited a typical AVP V-2 profile. [H-3]-SR 121463 also displayed a high affinity for native V-2 receptors in several kidney preparations from rat, pig, dog, rabbit, bovine, monkey, and human. The autoradiographic experiments using rat and human kidney sections showed intense labeling in the medullopapillary region and lower intensity in the cortex, consistent with a main localization of V-2 receptors on collecting tubules. Conclusion. [H-3]-SR 121463 is a useful ligand for the specific labeling of animal and human V-2 receptors and could be a suitable probe for the search and in situ localization of V-2 sites.
引用
收藏
页码:1613 / 1622
页数:10
相关论文
共 50 条
  • [1] Total synthesis of SR 121463 A, a highly potent and selective vasopressin V2:: Receptor antagonist
    Venkatesan, H
    Davis, MC
    Altas, Y
    Snyder, JP
    Liotta, DC
    JOURNAL OF ORGANIC CHEMISTRY, 2001, 66 (11): : 3653 - 3661
  • [2] An overview of SR121463, a selective non-peptide vasopressin V2 receptor antagonist
    Gal, CSL
    CARDIOVASCULAR DRUG REVIEWS, 2001, 19 (03): : 201 - 214
  • [3] Nonpeptide antagonists for vasopressin receptors -: Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist
    Serradeil-Le Gal, C
    VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES, 1998, 449 : 427 - 438
  • [4] Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension
    Lacheretz, F
    Barbier, A
    Serradeil-Le Gal, C
    Elena, PP
    Maffrand, JP
    Le Fur, G
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2000, 16 (03) : 203 - 216
  • [5] Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B), in patients with cirrhosis and ascites without hyponatremia
    Gines, Pere
    Wong, Florence
    Watson, Hugh R.
    Ruiz del Arbol, Luis R.
    Bilic, Ante
    Dobru, Daniela
    HEPATOLOGY, 2006, 44 (04) : 445A - 446A
  • [6] Aquaretic efficacy of the V2 vasopressin (AVP) receptor antagonist SR121463 in cirrhotic rats with ascites.
    Jimenez, W
    Serradeil-Le Gal, C
    Ros, J
    Cejudo, P
    Cano, C
    Rivera, F
    Arroyo, V
    Rodes, J
    HEPATOLOGY, 1999, 30 (04) : 232A - 232A
  • [7] Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B), on recurrence of ascites after large volume paracentesis
    Wong, Florence
    Gines, Pere
    Watson, Hugh
    Kujundzic, Milan
    Angeli, Paolo
    Horsmans, Yves
    HEPATOLOGY, 2006, 44 (04) : 256A - 256A
  • [8] Chemical development of the vasopressin receptor 2 antagonist SR-121463
    Hermecz, I
    Sánta-Csutor, A
    Gönczi, C
    Héja, G
    Csikós, É
    Simon, K
    Smelkó-Esek, A
    Podányi, B
    PURE AND APPLIED CHEMISTRY, 2001, 73 (09) : 1401 - 1409
  • [9] Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V-2 receptor antagonist
    SerradeilLeGal, C
    Lacour, C
    Valette, G
    Garcia, G
    Foulon, L
    Galindo, G
    Bankir, L
    Pouzet, B
    Guillon, G
    Barberis, C
    Chicot, D
    Jard, S
    Vilain, P
    Garcia, C
    Marty, E
    Raufaste, D
    Brossard, G
    Nisato, D
    Maffrand, JP
    LeFur, G
    JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (12): : 2729 - 2738
  • [10] Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia
    Gines, P.
    Wong, F.
    Milutinovic, S.
    del Arbol, L. Ruiz
    Olteanu, D.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S270 - S270